• Quanta

  Participated · Equity · Nov 2014

  Quanta Dialysis Technologies develops the Quanta Dialysis System to transform kidney care by enabling dialysis across multiple care settings. The system provides clinical versatility to perform intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED) and CRRT without bags, and in 2024 received FDA clearance for home hemodialysis with a high dialysate flow (500 mL/min). The device is designed to be operated by a broad range of users to bring dialysis directly to patients. Led by CEO Alejandro Galindo and based in Warwick, UK, the company aims to make dialysis accessible to every patient, in every setting. Quanta recently closed a Series E raising over $60M to support its US commercial expansion. The company plans to continue investing in innovation within the sector and scale its commercial footprint with support from new and existing investors. Quanta’s lead product, SC+, is a small, portable hemodialysis system that delivers the performance and dose equivalence of larger traditional machines while offering on‑demand dialysate production, high dialysate flow rates, digital connectivity and ease of use. The system uses a patented disposable cartridge for dialysate fluid management and pairs with a companion water‑purification module to create an all‑in‑one mobile stack that can run on a standard water supply. SC+ is FDA 510(k) cleared in the U.S. for use in acute and chronic care facilities and is CE marked in the U.K., where it has been used from ICU to clinic to the home. Quanta plans to scale global operations with a focus on the United States, investing in manufacturing, sales and customer service to support current approvals and market penetration. The company is preparing to launch a study to support future FDA clearance for in‑home use. The market opportunity is sizable, with a U.S. total addressable market projected to exceed $12 billion. The company is trans‑Atlantic, headquartered in the U.K. with operations in the U.S., and is now better capitalized following a major Series D raise. Quanta Dialysis Technologies develops SC+, a compact haemodialysis system designed for use in clinics and the home to empower patients to control their renal replacement therapy. The device uses a patented design that conducts all dialysate fluid management on a small, lightweight, disposable cartridge. SC+ is CE marked and has been piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional in-centre regimens. The company plans a UK commercial launch of SC+ and intends to submit a 510(k) to the FDA later this year. Quanta is led by CEO John E. Milad and was founded in 2008 in Alcester, Warwickshire, UK. The firm recently completed a first closing of Series C financing to support these plans. Quanta Fluid Solutions develops advanced haemodialysis systems, including its CE-marked portable, compact cartridge-based system called SC+. The company aims to expand its product line by developing a new nocturnal haemodialysis product concept using its cartridge platform. Funds from a £1.85M i4i award will support that development and advanced multi-physics modelling work. Quanta is collaborating with Professor William Zimmerman (Sheffield University) and Europlaz Technologies Ltd to advance cartridge technologies and modelling. Founded in 2008 as a spin-out from IMI plc, the company is based in Alcester, UK. Quanta has previously received funding from venture investors including NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company. Quanta Fluid Solutions develops SC+, a portable, compact haemodialysis system intended for use in clinics and the home. The company is led by CEO John E. Milad and is based in Alcester, UK. It was founded in 2008 as a spinout from FTSE 100 engineering company IMI plc. Quanta focuses on enabling dialysis outside traditional centres by delivering a compact, clinic- and home-capable platform. The company closed approximately £27m in funding. It intends to use the proceeds for the clinical introduction and commercial launch of SC+.

• CellNovo

  Participated · Series B · Feb 2011

  Cellnovo develops and markets a mobile, connected insulin pump system that pairs a touchscreen controller with an integrated blood-glucose meter for real-time data transmission and remote monitoring. The company is participating in multiple Artificial Pancreas projects (with Diabeloop, TypeZero and Horizon 2020) to develop automated insulin delivery systems. To support scaling, Cellnovo concluded a loan agreement with the European Investment Bank to aid its transition to full industrial-scale operations. The financing is intended to improve the Cellnovo System’s design to reduce production costs, add production lines, and fund multi-centre clinical trials of artificial pancreas solutions. The company signed the agreement in Paris on July 7, 2017; Sophie Baratte is the company’s CEO. Cellnovo is listed on Euronext (Compartment C, ISIN FR0012633360, Ticker CLNV). Cellnovo markets a compact, tubeless insulin pump system comprising a mobile touchscreen controller with an integrated blood‑glucose meter and automatic data transmission for remote monitoring by family and healthcare professionals. The company emphasizes drop‑by‑drop insulin delivery precision and patient freedom of movement. Over the first nine months of 2016 Cellnovo reported revenues of €1.054 million, €301,218 in Q3, shipped 68 new devices in Q3 and has sold 520 systems since launch. In Q3 2016 it raised circa €5.4 million via a capital increase and had a cash position of €15.6 million as of September 30, 2016. Net proceeds are being used to finance its artificial pancreas project from development through preparation for commercial launch, initially in Europe. Operationally it has limited new patient additions since Q2 to complete industrialisation of the consumable insulin cartridge and has not fulfilled all orders while ramping manufacturing capacity. Cellnovo develops a mobile-connected disease management system for people with diabetes. Led by CEO Bill McKeon, the company has built a mobile-connected micropump, a mobile touchscreen controller, a blood glucose meter and supporting applications. The system offers intuitive operation, wireless Internet connectivity and real-time activity tracking to remove the burden of keeping journals and to provide healthcare professionals with a real-time view of patient data. Cellnovo bundles hardware and software into an integrated diabetes management approach. The company intends to use the proceeds of its Series B financing to commercialize the system and expand into markets worldwide. It recently raised £30m in a Series B.

• Estech

  Participated · Equity · Dec 2010

  Estech is a San Ramon, California–based medical device company focused on a minimally invasive cardiac ablation platform that allows surgeons to treat atrial fibrillation endoscopically through three small chest ports. The procedure typically takes 60–90 minutes and, in some cases, can be performed under epidural rather than general anesthesia. The device holds a CE mark in Europe for treating atrial fibrillation and has received FDA 510(k) clearance for cardiac ablation in the United States. Estech’s technology aims to shorten procedure times and reduce patient trauma compared with traditional open-heart ablation surgeries. The company plans to use newly raised capital to advance further development of its platform. Over the past two years, Estech has secured more than $28 million in total funding, underscoring sustained investor confidence in its solution.

• SuperSonic Imagine

  Participated · Series C · Nov 2010

  SuperSonic Imagine develops the Aixplorer® MultiWave™ Ultrasound System, an ultrasound imaging platform cleared by the FDA and bearing CE mark approval. The company intends to use new capital to accelerate development of its technology and finance worldwide commercialization of Aixplorer. After an initial focus on breast imaging, SuperSonic plans to expand clinical applications to liver, thyroid, abdominal, musculoskeletal, gynecological and prostate imaging, and to enable future therapeutic capabilities. The company sells directly in France, Germany, the USA and the UK and operates through a worldwide distribution network, including Hologic for the U.S. breast care market and Canon in Japan. Founded in 2005, SuperSonic also maintains offices in Seattle, London and Munich.

• Symetis

  Led · Equity · Oct 2010

  Symetis is a Lausanne, Switzerland-based medical device company focused on transcatheter aortic valve implantation (TAVI) systems. Its lead product, Acurate TA™, is a self-aligning, nitinol stented tissue heart valve designed for trans-apical delivery, offering high positioning tolerance and ease of use. The company reported positive preliminary results from its first-in-man clinical study for Acurate TA™. Symetis is also developing Acurate TF™, a trans-femoral TAVI solution that is in pre-clinical validation and scheduled to enter clinical trials in 2011. The company raised CHF25M in equity financing to support commercial launch of its first product, clinical validation of Acurate TF™, and initiation of the US approval process. Board changes accompanied the financing, reflecting investor involvement in governance.

No current team members are available.